I disagree strongly, and believe that being on the OTCQB is a massive impediment to organic share price appreciation. Sure, it's happened with other stocks... but did those other stocks have the capital structure CytoDyn currently has? Not checking my numbers here, but the company has probably sold over 100 million shares to private placement investors in the last two years, complete with warrants, at a very low price. In other words, there's a massive amount of shares out there with a reasonable economic incentive to sell the shares and hold the warrants. To overcome that, you need buyers. As has been pointed out, mutual funds by and large can't touch OTC companies. Hedge funds can if they so choose, but you have to convince them, and then convince them not to flip on a 20% move. Most individual investors wouldn't dream of buying OTC stocks. We have a massive, massive supply and demand problem, and at least one side of that (demand) is greatly exacerbated by being on the OTC.
All of that said, I don't know where I stand on the RS issue. I would have taken the risk in April if the choice was mine, but I don't know if I would now.
Also, initial listing requirements for either the NYSE or NASDAQ require between $2 and $4 as a minimum bid. In most cases, you have to be at $4, but there are various criteria that a company could potentially qualify under with lower bids. Realistically, CYDY would likely need to be at $4. That's a long ways to go organically, given the supply/demand conundrum. Can it happen? Sure. But I think the only way we're getting there quickly is either a licensing deal on the diagnostic test with a sizeable up front payment or a solid partnership. Aside from that, I don't think we'll approach that level of appreciation (~700% gain...) until we see revenues. A couple hundred million a year in revenue from combo HIV would clean things up quickly.
